McKesson Corporation (MCK)
NYSE · Healthcare · Medical Distribution
$915.45+1.46%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $107B
- P/E (trailing)
- 24.5
- Forward P/E
- 18.1
- Dividend yield
- 0.4%
- 52-week range
- $723.68 – $999.00
- 52-week change
- +20.28%
- EPS (trailing)
- $37.31
- Analyst rating
- 1.6 Buy
- Next earnings
- Nov 4, 2026
Fiscal year to Mar 2026
- Revenue
- $403B (+12.36%)
- Net income
- $4.8B
- Operating margin
- 1.5%
- Diluted EPS
- $38.38
- Free cash flow
- $5.7B
From the company’s annual report on SEC EDGAR.
About McKesson Corporation
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions, and Medical-Surgical Solutions. The company distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products; delivers products to retail pharmacies, hospitals, long-term care centers, clinics, and institutions; and provides logistics and distribution services for manufacturers. It also provides consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies; gene therapy with InspiroGene, practice consulting, and vaccine distribution services; and technology solutions, as well as research, insights, technologies, and services to improve cancer and specialty care. In addition, the company helps in solving medication access, affordability, and adherence challenges for patients by working across healthcare to connect patients, pharmacies, providers, pharmacy benefit managers, health plans, and biopharma companies.
Headquarters: Irving, United States · 41,600 employees · mckesson.com